Melanotan 2 aparece con frecuencia en conversación y rara vez con contexto. Aquí van primero los fundamentos y después las consideraciones prácticas.
Actualizado el 2025-09-22. Las cifras y descripciones siguen la literatura publicada, no el material promocional.
5. Kidd, P. "Th1/Th2 Balance: the hypothesis, its limitations, and implications for health and disease". Alternative Medicine Review. 8: 223–46. 6. Ivashkiv, LB; Kalliolias, GD (2010). "Overview of the biology of type I interferons". Arthritis Research & Therapy. 12 (Suppl 1): S1. doi:10.1186/ar2881. 7. Vilcek, Novel interferons, Nature Immunol. 4, 8-9. 2003 8. Hermant, P, Michiels, T., Interferon-λ in the Context of Viral Infections: Production, Response and Therapeutic Implications.J Innate Immun (2014) Apr. 17 9. Fensterl V, Sen GC (2009). "Interferons and viral infections". BioFactors. 35 (1): 14–20. doi:10.1002/biof.6. PMID 19319841. 10. De Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR (2001). "Functional classification of interferon-stimulated genes identified using microarrays". Journal of leukocyte biology. 69 (6): 912–20. PMID 11404376. 10. 11. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T (2003). "Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence" (PDF). Nature. 424 (6948): 516–23. Bibcode:2003Natur.424..516T. doi:10.1038/nature01850. PMID 12872134. 12. Moiseeva O, Mallette FA, Mukhopadhyay UK, Moores A, Ferbeyre G (2006). "DNA Damage Signaling and p53-dependent Senescence after Prolonged β-Interferon Stimulation". Mol. Biol. Cell. 17 (4): 1583–92. doi:10.1091/mbc.E05-09-0858. PMC 1415317 Freely accessible. PMID 16436515. 13. Whitehead KA, Dahlman JE, Langer RS, Anderson DG (2011).
Fuentes: es.wikipedia.org
"Silencing or stimulation? siRNA delivery and the immune system". Annu Rev Chem Biomol Eng. 2: 77–96. doi:10.1146/annurev-chembioeng-061010-114133. PMID 22432611. 14. Haller O, Kochs G, Weber F (October–December 2007). "Interferon, Mx, and viral countermeasures". Cytokine Growth Factor Rev. 18 (5–6): 425–33. doi:10.1016/j.cytogfr.2007.06.001. PMID 17683972. 15. Platanias LC (May 2005). "Mechanisms of type-I- and type-II-interferon-mediated signalling". Nature Reviews. Immunology. 5 (5): 375–386. doi:10.1038/nri1604. PMID 15864272. 16. Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ (January 2009). "INTERFEROME: the database of interferon regulated genes.". Nucleic Acids Res. 37: D852–7. doi:10.1093/nar/gkn732. PMC 2686605 Freely accessible. PMID 18996892. 17. Navratil V, de Chassey B, Meyniel L, Pradezynski F, André P, Rabourdin-Combe C, Lotteau V (2010-11-05). "Systems-level comparison of protein-protein interactions between viruses and the human type I interferon system network". Journal of Proteome Research. 9 (7): 3527–36. doi:10.1021/pr100326j. PMID 20459142. 18. Lin RJ, Liao CL, Lin E, Lin YL (September 2004). "Blocking of the Alpha Interferon-Induced Jak-Stat Signaling Pathway by Japanese Encephalitis Virus Infection". J. Virol. 78 (17): 9285–94. doi:10.1128/JVI.78.17.9285-9294.2004. PMC 506928 Freely accessible. PMID 15308723. 19. Sen GC (2001). "Viruses and interferons". Annu. Rev. Microbiol. 55: 255–81. doi:10.1146/annurev.micro.55.1.255. PMID 11544356. 20. Alcamí A, Symons JA, Smith GL (December 2000).
Fuentes: es.wikipedia.org
"The Vaccinia virus soluble Alpha/Beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN". J. Virol. 74 (23): 11230–9. doi:10.1128/JVI.74.23.11230-11239.2000. PMC 113220 Freely accessible. PMID 11070021. 21. Minks MA, West DK, Benvin S, Baglioni C (October 1979). "Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells". J. Biol. Chem. 254 (20): 10180–3. PMID 489592. 22. Miller JE, Samuel CE (September 1992). "Proteolytic cleavage of the reovirus sigma 3 protein results in enhanced double-stranded RNA-binding activity: identification of a repeated basic amino acid motif within the C-terminal binding region". J. Virol. 66 (9): 5347–56. PMC 289090 Freely accessible. PMID 1501278. 23. Chang HW, Watson JC, Jacobs BL (June 1992). "The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase". Proc. Natl. Acad. Sci. U.S.A. 89 (11): 4825–9. Bibcode:1992PNAS...89.4825C. doi:10.1073/pnas.89.11.4825. PMC 49180 Freely accessible. PMID 1350676. 24. Seo SH, Hoffmann E, Webster RG (August 2002). "Lethal H5N1 influenza viruses escape host anti-viral cytokine responses". Nature Medicine. 8 (9): 950–954. doi:10.1038/nm757. PMID 12195436. 25. Paolicelli D, Direnzo V, Trojano M (14 September 2009). "Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis". Biologics: Targets & Therapy. 3: 369–376. PMC 2726074 Freely accessible. PMID 19707422. 26.
Fuentes: es.wikipedia.org
Goldstein D, Laszlo J (Sep 1988). "The role of interferon in cancer therapy: a current perspective" (Free full text). CA: A Cancer Journal for Clinicians. 38 (5): 258–277. doi:10.3322/canjclin.38.5.258. PMID 2458171. 27. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM (Mar 2008). "Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion". Cancer. 112 (5): 982–994. doi:10.1002/cncr.23251. PMID 18236459. 28. Cooksley WG (Mar 2004). "The role of interferon therapy in Hepatitis B". MedGenMed : Medscape general medicine. 6 (1): 16. PMC 1140699 Freely accessible. PMID 15208528. 29. Shepherd J, Waugh N, Hewitson P (2000). "Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review" (Free full text). Health technology assessment (Winchester, England). 4 (33): 1–67. PMID 11134916. 30. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. 31. Ishikawa T (Oct 2008). "Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients" (Free full text). World Journal of Gastroenterology. 14 (40): 6140–6144. doi:10.3748/wjg.14.6140.
Fuentes: es.wikipedia.org
Melanotan 2 se resume aquí a partir de literatura pública: definición, contexto y los puntos que se repiten en la práctica. Información general, no consejo médico.
La investigación sobre Melanotan 2 se apoya sobre todo en estudios de laboratorio y en modelos animales; los datos clínicos varían según la sustancia. Reflejamos el estado de la literatura.
Lo decisivo son la pureza y la analítica (HPLC, espectrometría de masas), una reconstitución correcta y un almacenamiento adecuado.%!(EXTRA string=Melanotan 2)
No todos los mecanismos están demostrados y un estudio aislado no es evidencia global. Esta página señala las preguntas abiertas en lugar de darlas por resueltas.%!(EXTRA string=Melanotan 2)